Caxton Corp Aclaris Therapeutics, Inc. Transaction History

Caxton Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.56 - $10.95 $127,742 - $213,229	19,473 New	19,473 $133,000
Q1 2019 May 14, 2019	SELL	$5.63 - $7.84 $344,916 - $480,309	-61,264 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$6.3 - $15.4 $135,506 - $331,238	21,509 Added 54.1%	61,264 $453,000
Q3 2018 Nov 14, 2018	BUY	$14.38 - $20.89 $291,065 - $422,834	20,241 Added 103.73%	39,755 $577,000
Q2 2018 Aug 14, 2018	SELL	$16.46 - $20.33 $26,796 - $33,097	-1,628 Reduced 7.7%	19,514 $0
Q1 2018 May 15, 2018	BUY	$17.08 - $25.64 $53,767 - $80,714	3,148 Added 17.49%	21,142 $370,000
Q4 2017 Feb 14, 2018	BUY	$21.47 - $27.8 $167,852 - $217,340	7,818 Added 76.83%	17,994 $444,000
Q3 2017 Nov 14, 2017	BUY	$23.02 - $28.8 $234,251 - $293,068	10,176	10,176 $263,000

52.4M

32.4K

3.3K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $139M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.